AAAAAA
Results:
1-17
|
Results: 17
Authors:
Workman, P
Citation: P. Workman, Signal transduction pathways - A goldmine for therapeutic targets, CANC DRUG, 8, 2001, pp. 1-20
Authors:
Huang, CC
Fierke, CA
Casey, PJ
Citation: Cc. Huang et al., The biochemistry of farnesyltransferase and geranylgeranyltransferase I, CANC DRUG, 8, 2001, pp. 21-36
Authors:
Long, SB
Beese, LS
Citation: Sb. Long et Ls. Beese, Structures of protein farnesyltransferase, CANC DRUG, 8, 2001, pp. 37-48
Authors:
Knowles, D
Sun, JZ
Rosenberg, S
Sebti, SM
Hamilton, AD
Citation: D. Knowles et al., Peptidomimetic-based inhibitors of farnesyltransferase, CANC DRUG, 8, 2001, pp. 49-64
Authors:
Gibbs, JB
Graham, SL
Hartman, GD
Koblan, KS
Kohl, NE
Omer, C
Pellicier, A
Windle, J
Oliff, A
Citation: Jb. Gibbs et al., Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice, CANC DRUG, 8, 2001, pp. 65-70
Authors:
Manne, V
Lee, F
Yan, N
Fairchild, C
Rose, WC
Citation: V. Manne et al., Development of farnesyltransferase inhibitors as potential antitumor agents, CANC DRUG, 8, 2001, pp. 71-86
Authors:
Bishop, WR
Pai, JJK
Armstrong, L
Dalton, MB
Doll, RJ
Taveras, A
Njoroge, G
Sinensky, M
Zhang, F
Liu, M
Kirschmeier, P
Citation: Wr. Bishop et al., Tricyclic farnesyl protein transferase inhibitors - Antitumor activity andeffects on protein prenylation, CANC DRUG, 8, 2001, pp. 87-101
Authors:
Sebolt-Leopold, JS
Leonard, DM
Leopold, WR
Citation: Js. Sebolt-leopold et al., Histidylbenzylglycinamides - A novel class of farnesyl diphosphate-competitive peptidic farnesyltransferase inhibitors, CANC DRUG, 8, 2001, pp. 103-114
Authors:
Mailliet, P
Laoui, A
Bourzat, JD
Capet, M
Cheve, M
Commercon, A
Dereu, N
LeBrun, A
Martin, JP
Peyronel, JF
Salagnad, C
Thompson, F
Zucco, M
Guitton, JD
Pantel, G
Bissery, MC
Brealey, C
Lavayre, J
Lelievre, Y
Riou, JF
Vrignaud, P
Duchesne, M
Lavelle, F
Citation: P. Mailliet et al., From random screening of chemical libraries to the optimization of FPP-Competitive inhibitors of farnesyltransferase, CANC DRUG, 8, 2001, pp. 115-144
Authors:
Tamanoi, F
Del Villar, K
Robinson, N
Kim, M
Urano, J
Yang, WL
Citation: F. Tamanoi et al., Genetic analysis of FTase and GGTase I and natural product farnesyltransferase inhibitors, CANC DRUG, 8, 2001, pp. 145-157
Authors:
Prendergast, GC
Citation: Gc. Prendergast, Effects of farnesyltransferase inhibitors on cytoskeleton, cell transformation, and tumorigenesis - The FTI-Rho hypothesis, CANC DRUG, 8, 2001, pp. 159-169
Authors:
Bernhard, EJ
Muschel, RH
Cohen-Jonathan, E
Favre, G
Hamilton, AD
Sebti, SM
McKenna, WG
Citation: Ej. Bernhard et al., Prenyltransferase inhibitors as radiosensitizers, CANC DRUG, 8, 2001, pp. 171-195
Authors:
Sebti, SM
Hamilton, AD
Citation: Sm. Sebti et Ad. Hamilton, Farnesyltransferase and geranylgeranyltransferase I inhibitors as novel agents for cancer and cardiovascular diseases, CANC DRUG, 8, 2001, pp. 197-219
Authors:
Gelb, MH
Buckner, FS
Yokoyama, K
Ohkanda, J
Hamilton, AD
Nguyen, L
Rossi-Bergmann, B
Stuart, KD
Sebti, SM
Van Voorhis, WC
Citation: Mh. Gelb et al., Protein prenylation in trypanosomatids - A new piggy-back medicinal chemistry target for the development of agents against tropical diseases, CANC DRUG, 8, 2001, pp. 221-232
Authors:
Patnaik, A
Rowinsky, EK
Citation: A. Patnaik et Ek. Rowinsky, Early clinical experience with farnesyl protein transferase inhibitors - From the bench to the bedside, CANC DRUG, 8, 2001, pp. 233-249
Authors:
Hudes, GR
Schol, J
Citation: Gr. Hudes et J. Schol, Phase I trial of oral R115777 in patients with refractory solid tumors - Preliminary results, CANC DRUG, 8, 2001, pp. 251-254
Authors:
Cox, AD
Toussaint, LG
Fiordalisi, JJ
Rogers-Graham, K
Der, CJ
Citation: Ad. Cox et al., Farnesyltransferase and geranylgeranyltransferase inhibitors - The saga continues, CANC DRUG, 8, 2001, pp. 255-273
Risultati:
1-17
|